Why Phibro Animal Health stock is on investors’ radar

Recent trading in Phibro Animal Health (PAHC) has drawn attention, with the share price at $54.89 and total return data over the past month and past 3 months prompting closer scrutiny of the business fundamentals.

That recent one day share price return of 3.22% sits on top of a 36.71% 90 day share price return and a very large 1 year total shareholder return, which suggests momentum has been building rather than fading.

If strong recent gains in PAHC have you rethinking where growth could come from next, it may be worth scanning for other potential movers through 18 top founder-led companies

With PAHC trading above its US$51.20 analyst price target yet showing a 54% intrinsic discount estimate, investors face a key question: is this surge overdone, or is the market only starting to price in future growth?

Most Popular Narrative: 13% Overvalued

The widely followed narrative puts Phibro Animal Health's fair value at $48.50, below the last close of $54.89, and builds its case around specific growth and margin expectations.

The company's strong recent growth is heavily dependent on the integration of the acquired Zoetis Medicated Feed Additive business and related cost synergies, which are non repeatable. Forward guidance suggests legacy product growth will slow to flat or low single digits, implying the current trajectory of accelerating revenue and EBITDA growth is unsustainable and likely to normalize, impacting revenue and earnings growth expectations.

Want to see what keeps that fair value below the current price? The core story hinges on how revenue, margins and future earnings are modelled over time, plus the single discount rate used to pull all those cash flows back to today.

Result: Fair Value of $48.50 (OVERVALUED)

However, strong secular demand for animal protein and the integration of the Zoetis feed additive portfolio could keep earnings and margins firmer than this cautious view implies.

Another Way To Look At Value

That narrative fair value of $48.50 presents Phibro Animal Health as 13% overvalued at $54.89, while the SWS DCF model indicates a future cash flow value of $119.16 and a 54% intrinsic discount. Which perspective do you think better fits your expectations?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Phibro Animal Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across price, fair value and future expectations, sentiment here is far from one sided. Take a closer look now and weigh both the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If this Phibro Animal Health story has you thinking about where to put fresh capital next, do not stop at one stock when better fits may be waiting.

• Target dependable cash generators by checking companies screened for resilient balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for pricing gaps where quality and value meet using the 51 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks built around steady payouts and high yields via the 13 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.